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Multiple sclerosis (MS) is a disorder of the cen-
tral nervous system (CNS) characterized by perivas-
cular inflammation and demyelination in the white
m a t t e r. The etiology and pathogenesis of MS is u n-
known, although it is a complex phenomenon in-
volving both genetic and environmental aspects.
These forces interact to produce individual suscep-
tibility to the disease and influence its course1. Al-
though MS is a disease of the CNS, the peripheral
blood and cere b rospinal fluid (CSF) of patients con-
tain activated autoreactive T cells recognizing my-
elin components such as myelin basic protein ( M B P ) ,
p roteolipid protein (PLP), myelin associated glyco-
p rotein and myelin oligodendrocyte glycopro t e i n
( M O G )2. Activated T lymphocytes also produce cy-
tokines that modulate the immune response either
positively or negatively. Some of these cytokines
have pro i n f l a m m a t o ry effects enhancing inflam-
m a t o ry reactions; whereas others have anti-inflam-
m a t o ry pro p e rties. The cytokines produced by Th1
cells, such as tumor necrosis factor alpha (TNFα)
and interf e ron gamma (IFNγ), may promote the
p ro g ress of the disease3 , 4, while those pro d u c e d
by the Th2/Th3 subsets, such as interleukin 10 (IL10)
and transforming growth factor beta (TGFβ), may
limit it5. Some authors have also re p o rted the im-
p o rtant contribution of antibodies in the initia-
tion of myelin sheath damage in MS6.
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ABSTRACT - Cytokines and intrathecal IgG synthesis were determined in the cerebrospinal fluid (CSF) and
sera to evaluate inflammatory activity in multiple sclerosis (MS) patients during clinical remission. Although
the disease was stable, there had been a significant increase of pro i n f l a m m a t o ry cytokines such as TNFα
and IFNγ in the CSF and serum, with no significant changes of IL12 and IL10 production. The changes in t h e
cytokine production patterns were associated with an increase of leukocytes in the CSF, as well as the pre s-
ence of oligoclonal bands suggesting intrathecal IgG synthesis. These results suggest that even when the
disease is clinically silent, one can observe inflammatory activity in these MS patients. 
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Citocinas e síntese intratecal de IgG em pacientes com esclerose múltipla durante remissão clínica
RESUMO - Os níveis de citocinas e síntese intratecal de IgG foram dosados no líquido cefalorr a q u i d i a n o
(LCR) e soro, com o objetivo de avaliar a atividade inflamatória em pacientes com esclerose múltipla durante
remissão clínica. Foram detectados níveis elevados de citocinas pró-inflamatórias (TNFα e IFNγ) no LCR e
s o ro, sem alterações significativas na produção de IL12 e IL10. O perfil de produção das citocinas pró-infla-
matórias estava associado ao aumento de leucócitos no LCR, assim como a presença de bandas oligoclona-
is IgG sugerindo síntese intratecal de IgG. Estes resultados sugerem que mesmo quando a doença está clini-
camente silenciosa, a atividade inflamatória está presente nestes pacientes.
PALAVRAS-CHAVE: esclerose múltipla, líquido cefalorraquidiano, citocinas, IgG síntese intratecal.
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For diagnosis, magnetic resonance imaging ( M R I )
has shown great potential as an indicator of disea-
se activity in patients with MS7, with the use of CSF
analysis receiving less attention. However, the CSF
analysis is still a valuable tool and in association w i t h
imaging data provide reliable information about
the inflammatory status of a patient.
In the present study, we assessed serum and CSF
levels of cytokines, leukocytes count and intrathe-
cal IgG synthesis to evaluate inflammatory activit y
in a subgroup of untreated MS Brazilian patients
during clinical remission.
METHOD
Patients – Patients were re c ruited at the hospital of
the University of Campinas, located in Campinas, SP, Bra-
zil, during the period of 2002-2004. A total of 58 indivi-
duals (42 women and 16 men) were included in the stu-
d y. At that time, the individuals were divided into thre e
g roups: I. 23 clinically definite MS patients (6 men, 17 wo-
men, the mean age was 30) with a re l a p s i n g - re m i t t i n g
f o rm of disease (RRMS) according to Poser criteria8; II. 16
patients with other neurologic diseases (3 men, 13 wo-
men, the mean age was 33): 4 with motor neuron disea-
se, 2 with here d i t a ry sensory-motor neuro p a t h y, 2 with
Parkinson´s disease, 4 with epilepsy, 2 Alzheimer´s disease,
2 with cere b rovascular disease; III. 19 individuals (7 men,
12 women, the mean age was 31 years) with backache or
headache and who had no evidence of organic neuro l o g-
ical disease, studied as a healthy control group. The pati-
ents with clinically definite MS who were seen in our MS
clinic were studied. MRI and laboratory investigations
w e re perf o rmed during the initial contact for diagnosis
purposes and the determination that the patients were
in remission, without treatment. The delay between first
attack and first consultation was 4.2 ± 3.8 years. The Ex-
panded Disability Status Scale (EDSS) score was determ i n e d
at lumbar puncture. None of the patients had re c e i v e d
c o rt i c o s t e roids or other immunosuppressive drugs during
a period of at least 6 months prior to donating CSF and
blood for the study. The study was approved by the
Medical Ethics Committee of the hospital, and inform e d
consent was obtained.
Samples – All specimens were obtained for the ro u-
tine determination of CSF leukocyte count, IgG synthe-
sis and oligoclonal IgG bands. Paired samples of seru m
and CSF were stored at - 80o C until these exams were
p e rf o rmed. The CSF (10 mL) was taken and cell counting
done quickly before sampling. 
L a b o r a t o ry pro c e d u res – IgG and albumin in the CSF
and serum were measured by nephelometry (BNII; Dade
Behring, Marburg, Germany), and Link Indexes (LI) were
calculated according to the literature9. Oligoclonal IgG
bands were identified by isoelectrofocusing10. 
Antigen, antibody and recombinant cytokines – T h e
IL12, IFNγ, TNFα, and IL10 were quantified using com-
m e rcial kits from Biosource International, Nivelles, Bel-
gium. All measure was made at the single occasion in
o rder to minimize the intra assay variability. Briefly, 96-
well microtiter plates were coated with 1-2 ρg/mL of
c a p t u re monoclonal antibody for each cytokine in 0.1M
N a H C O3 (pH= 8.5) and allowed to incubate overn i g h t
at 4oC. Following blocking with 3% dry milk in PBS at
room temperature for 2 h, samples and standard re c o m-
binant IFNγ, TNFα, IL10 and IL12 were added again and
incubated overnight at 4º C. Then, 0.5-2.0 ρg/mL of bio-
tinylated detection monoclonal antibody for human
IL12, IFNγ, TNFα and IL10 were added, followed by the
addition of avidin-peroxidase 1/400 (Sigma Chem.- USA)
and the peroxidase substrate. A stop solution was used
to obtain OD determined at 492 nm.
Imaging – MRIs were perf o rmed, using a 2.0 Te s l a
s y stem (Elscint, Pre s t i g eR). All exams covered the whole
brain using 6.0 mm slice thick and 1.2 mm inter- s l i c e
gap. MRI acquisition parameters for images used for
analysis were: T1 sagittal images and T2 axial.
Statistics – The statistical significance of the results was
d e t e rmined using a non-parametric analysis of variance,
and a Kru s k a l - Wallis test and Spearman Rank test. A p v a l-
ue smaller than 0.05 was considered to be significant.
RESULTS
Twenty three patients with MS were evaluat-
ed (Table 1). Brain MRI showed abnormalities with
demyelinating lesions in 23 (100 %) and pre s e n c e
of gadolinium-enhancing lesions in 5 (21 %) of the
23 MS patients. These patients showed CSF hyper-
cytosis and intrathecal IgG synthesis. Twenty-one
(91.3 %) MS patients were oligoclonal bands (OCB)
positive.
CSF data and patients characteristics of the
g roups are shown in Table 2. The percentage of
patients with hypercytosis was increased in the MS
g roup when compared with the group II (other n e u-
rologic diseases; p= 0.004) and group III (healthy
controls; p= 0. 0001). 
P roduction of TNFα in CSF and serum of pa -
tients with MS, other neurological disorders, as w e l l
as healthy controls – The means for MS patients
w e re 137.3 ± 119.7 and 116.0 ± 115 pg/ml in seru m
and CSF, respectively; whereas for the OND gro u p
these were 7.6 ± 24.1 and 8.6 ± 28.4 pg/ml for se-
rum and CSF, respectively; for the healthy contro l s ,
these values were 15.3 ± 19.8 and 4.3 ± 8.2 pg/ml.
A significant increase (p<0.001) in TNFα was obser-
ved in the CSF, and serum of patients with MS.
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T N Fα levels in the CSF exceeded those in the seru m
for 10/23 patients, suggesting an intrathecal syn-
thesis (Fig 1A). There was a positive corre l a t i o n
between the number of leukocytes in the CSF and
the level of TNFα (R2 = 0.6874, p= 0.001).
Production of IL12p40 in CSF and serum – The
means for MS patients were 49.1 ± 18.3 and 39.4
± 13.2 pg/mL for serum and CSF, respectively; whe-
reas for the OND group they were 76.2 ± 32.2 and
58.1 ± 35.1 pg/mL; for the healthy controls these
means were 57.4 ± 18.8 and 45.4 ± 15.3 pg/mL. No
significant diff e rence (p>0.05) were observed bet-
ween the three groups (Fig 1 B). 
P roduction of IFNγ in CSF and serum patients
with MS and, other neurological disorders, as well
as healthy contro l s – The means for MS patients
w e re 500.9 ± 169.5 and 359.0 ± 85.1 pg/mL in se-
rum and CSF respectively; whereas for the OND
g roup, these were 418.6 ± 67.0 and 325.2 ± 70.5
pg/mL; for the healthy controls these mean were
102.6 ± 102.7 and 54.1 ± 39.6 pg/mL. A significant
i n c rease (p< 0.001) in the IFNγ was observed in
both CSF and serum of patients with both MS and
OND (Fig 1C).
P roduction of IL-10 in CSF and serum – The m e a n s
for MS patients were 304.6 ± 112.0 and 287.6 ±
Table 1. Clinical and laboratory data of relapsing-remitting multiple sclerosis group.
Patient Age, y Sex DD N.rel. EDSS1 Cells Alb- I IgG- I OB IgG
1 44 M 1 2 1 8 2.6 0.65 +
2 32 M 3 4 2.5 15 5.23 0.51 -
3 32 F 3 3 1.5 20 3.64 3.35 +
4 37 M 3 5 2 2 2.82 1 +
5 30 F 4 4 3 3 2.25 0.82 +
6 22 F 4 5 2 16 2.4 0.98 +
7 10 F 8 2 2 14 5.84 0.84 +
8 25 F 7 4 1.5 13 2.7 1.49 +
9 43 M 9 6 2 1 7.97 1.12 +
10 24 F 2 4 2 15 3.25 0.76 +
11 46 F 9 3 3 13 6.4 1.73 +
12 43 F 12 6 2.5 3 4 0.88 +
13 33 F 5 4 1.5 1 5.13 0.67 +
14 35 F 13 5 2 3 1.97 1.52 +
15 29 F 11 3 1 16 5.9 0.81 +
16 43 M 8 2 2 1 1.66 0.59 -
17 25 F 5 4 2 5 3.44 0.83 +
18 13 M 3 9 2 24 4 0.74 +
19 21 M 7 3 1 5 6.17 0.6 +
20 37 F 1 2 1.5 18 5.1 2.37 +
21 21 F 7 6 1.5 5 5.35 1.66 +
22 39 F 6 2 1 4 5.37 1.03 +
23 40 F 4 3 2.5 5 4 0.8 +
DD, duration of disease; EDSS1, Expanded Disability Status Scale at the time of the study; Alb-I, albumin index; IgG-I, IgG index; OB IgG, oligo-
clonal IgG bands; N.rel., number of relapses; y, years.
Table 2. Patients characteristics, number of CSF leukocytes, intrathecal IgG synthesis index and oligoclonal bands.
Patients Age, y (mean± SD) Te, y Sex, M/F Cells IgG-index OB IgG+
MS (23) 30± 9 5 ± 3 6/ 17 9.13 ± 7.05 1.12 ± 0.66 21/ 23
ODN (16) 31± 10 6 ± 3 3/ 13 4.19 ± 5.55 0.53 ± 0.13 1/ 16
HC (19) 37 ± 16 - 6/ 13 1.47 ± 0.77 0.45 ± 0.12 0/ 19
MS, multiple sclerosis; ODN, other neurologic diseases; HC, healthy controls; OB, oligoclonal bands; Te, time of evolution; y, years; SD, standard
deviation.
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113.7 pg/mL for serum and CSF, respectively; whe-
reas for the OND group they were 507.6 ± 187.1
and 424.3 ± 113.7 pg/mL for serum and CSF, re s p e c-
tively; for the healthy controls, these means were
354.6 ± 111.4 and 296.2 ± 74.8 pg/mL. No signifi-
cant diff e rences were found between the patients
with MS and healthy controls (p>0.05), where a s
the OND group of patients revealed significantly
higher levels of IL 10 (p=0.006) (Fig 1D).
DISCUSSION
The purpose of this investigation was to evalu-
ate inflammatory activity in MS patients during
clinical remission. Our results showed that patients
with MS which is identified stable phase of the dis-
ease reveal increase in the secretion of pro - i n f l a m-
m a t o ry cytokines in both serum and CSF associat-
ed with the increase in the intrathecal synthesis
of IgG and the number of leukocytes in the CSF. T h i s
study demonstrated that patients with stable RRMS
have an elevated number of leukocytes in the CSF
when compared with patients with other non-in-
f l a m m a t o ry diseases of CNS and healthy contro l s .
Other studies suggested that the presence of white
blood cells in the CSF is a good predictor of the
activity of MS, since after two years, patients with
a high number of white blood cells in the CSF had
more relapses than those in control group11. 
Parallel to the increase of the number of cells
there is also the presence of oligoclonal bands in
91% of studied MS patients. These results are in
a g reement with previous Brazilian re p o rt s1 2 , 1 3. Al-
though the antibody specificity in the oligoclonal
bands is still enigmatic, as suggested by re p o rts in
the literature, a lack of intrathecal synthesis of ol-
igoclonal IgG bands is related to short lasting and
benign course of MS14.
The B-cell proliferation, diff e rentiation and an-
tibody production is coordinated by the helper T
cells and the cytokines they produce. Although
Th1 and Th2 cells are the major sources of their
respective cytokines, many others cells within and
outside the immune system also produce these
cytokines, contributing to an overall Th1 and Th2
cytokine pattern. It was thus decided to quantify
both pro and anti-inflammatory cytokines in the
CSF and the serum, independent of their source.
The cytokines produced in the early phase of
i n f l a m m a t o ry response, such as IL12, contribute
to the development of Th1 immune response. Con-
flicting results re g a rding IL12 production have,
h o w e v e r, been observed in MS. An increase in the
production of this cytokine has been observed in
progressive MS15 and increased frequencies of IL-
12 secreting monocytes appear to correlate with
Fig 1. Production of cytokines (TNFα, IL 12, IFNγ and IL 10 ) in the CSF and sera from MS patients, OND (oth -
er neurologic diseases) and healthy controls, detected by ELISA.
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the presence of active brain lesions detected by
M R I1 6. Serum levels of IL12, however, have been
found to be similar in MS patients and controls17.
In the present study, as well, no change in the pro-
duction of this cytokine was observed in the seru m
or CSF of MS patients. It seems that, blood monocy-
tes must be stimulated in order to produce detec-
table amounts of IL12, but since we did not use
activated cells, the production of IL12 may have
been too low to be detected in the ELISA assay.
The IFNγ of MS patients, on the other hand,
showed significant increase in the CSF and serum
over that of healthy controls, although no diff e re n-
ce was observed in relation to the OND group. Ini-
t i a l l y, interf e rons were tested as therapeutic agents
for MS because of their antiviral pro p e rties and it
was felt that MS might be due to persistent viral
infection. However, a pathogenic role for MS pa-
tients who received recombinant IFNγ t re a t m e n t
in MS has been re p o rt e d1 8. Our data support pre v i-
ous ones which demonstrated that IFNγ has potent
p ro i n f l a m m a t o ry response, including the ability
to induce the production of other pro i n f l a m m a t o-
ry cytokines1 9. In the animal model, the pro d u ct i o n
of isotypes of IgG, such as IgG2a is induced by the
I F Nγ. In our findings, no information is given about
the subclass of IgG, which is increased in the CSF
of MS patients, but it is possible that the incre a s e
in intrathecal IgG production is due to the incre a s e
in intrathecal synthesis of IFNγ. 
In addition to the production of IFNγ, there was
a parallel increase of TNFα in the serum and CSF.
A p p roximately 40 % of the MS patients pre s e n t e d
levels of TNFα in the CSF equal to or greater than
that in the serum, suggesting the intrathecal syn-
thesis of this cytokine. TNFα has been described as
a major cytokine in this demyelinating disease, since
it has been demonstrated to be myelinotoxic2 0 - 2 3.
T N Fα is also a major inducer of endothelial adhe-
sion molecules and chemokines, hence, the upre g u-
lation TNFαmay have a major effect on the re c ru i t-
ment of leukocytes to the CNS2 4. In this study it was
possible to show a positive correlation between the
number of leukocytes in the CSF and the level of
T N Fα. This pro p e rty may explain, at least in part, the
i n c reased number of inflammation-perpetuating
leukocytes observed in the CSF in MS patients.
Elevation in CSF concentrations of soluble ICAM-1
and soluble TNFα receptor were demonstrated pre-
viously in Brazilian MS patients with acute re l a p s-
ing form of MS during exacerbation2 5.
As the inflammatory response develops, the cy-
tokine products of Th1 or Th2 lymphocytes pro v i-
de mutually inhibitory functions for the diff e re n t i a-
tion and effector effect of the re c i p rocal phenoty-
pe. IFNγ p revent Th2 cell proliferation, whereas I L 1 0
p rofoundly inhibits the synthesis of Th1 cytokines2 6.
Reports on the IL-10 production showed that pa-
tients with high IL-10 production had significant-
ly lower disability scores and lower T2 lesion load2 7.
In the present study, we did not observe signifi-
cant changes in IL10 levels in MS patients. These
data agree with that of studies demonstrating a
reduction in IL10 levels in the serum, as well as in
the number of IL10-secreting cells in MS pati-
e n t s1 9 , 2 8 - 3 0, re i n f o rcing the fact that the pro i n f l a m-
m a t o ry response prevails in this group of patients,
despite the absence of clinical manifestation.
This study provides evidence of a significant in-
c rease in inflammatory activity in patients with
stable MS over that in the control groups. These
observations suggest that an investigation of the
inflammatory parameters in the CSF may provide
a valuable tool, which would be useful in the in-
dication of activity of the disease, thus helping un-
derstand the damages caused by the inflammato-
ry response.
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